Composition
Each tablet contains:
Rofecoxib                    12.5 or 25 mg

Properties and Mode of Action
RHUMA-CURE is a NSAID which inhibits prostaglandin synthesis by COX-2 inhibition.So, it has analegesic and anti-inflmmatory actions with low incidence of gastrointestinal side effects.

Indications
Relief of signs and symptoms of osteoarthritis.
Relief of acute pain.
Treatment of Primary Dysmenorrhoea.

Dosage and Administration
Osteoarthritis:
12.5 - 25 mg Once Daily.
Acute Pain and Primary Dysmenorrhoea:
50 mg Once Daily ( for not more than 5 days).

Precautions
Caution should be used in patients with advanced renal dysfunction, moderate to severe hepatic dysfunction, patients with hypertension, heart failure and pre-existing asthma or prior history of peptic ulcer or GI bleeding. Used in pregnancy and lactation only if the potential benefit justifies the potential risk. RHUMA-CURE use during the third trimester of pregnancy should be avoided.

Drug Interactions
RHUMA-CURE can be used with low-dose aspirin and other anti-inflammatory drugs; however, care should be taken when combining RHUMA-CURE with those drugs, because gastric irritation may result.
NSAIDs may diminish the antihypertensive effect of ACE inhibitors and reduce the natriuretic effect of furosemide and thiazides . This interaction should be given consideration in patients taking RHUMA-CURE concomitantly with ACE inhibitors and diuretics.
NSAIDs can elevate plasma Lithium levels and reduce its renal clearance; patients taking RHUMA-CURE and lithium concurrently should be observed for signs of lithium toxicity.
Rifampin 600 mg daily produced a 50% decrease in rofecoxib plasma concentration. A starting daily dose of 25 mg RHUMA-CURE should be considered for osteoarthritis treatment when co-administrated with rifampin.
RHUMA-CURE effects of recommended doses for osteoarthritis (12.5 and 25 mg) on plasma Methotrexate levels are unknown. Standard monitoring of Methotrexate toxicity should be observed when RHUMA-CURE and methotrexate are administered concomitantly.
Prothrombin time increased in healthy individuals receiving RHUMA-CURE and warfarin but this is unlikely to be clinically important in most patients.
Standard monitoring of PT values should be conducted when RHUMA-CURE is initiated or changed, particularly in the first few days, in patients receiving warfarin or similar agents.

Contra_indications
Hypersensitivity to Rofecoxib. Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDS.

Side effects
RHUMA-CURE is generally well-tolerated. Indigestion, heartburn, nausea, diarrhoea, hypertension and lower extremity oedema, dizziness, sinusitis, urinary tract infection, asthenia and fatigue may occur.

Presentation
RHUMA-CURE 12.5 mg Tablets : Box of 1 blister of 10 tablets.
RHUMA-CURE 25 mg Tablets : Box of 1 blister of 10 tablets.